KalVista executive sells $905,000 in shares ahead of Chiesi buyout
The Chief Development Officer retains a $6.16 million stake as the company navigates a pending $27 per share deal from Chiesi Group.
Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, has sold 33,800 shares for approximately $905,000, according to a Securities and Exchange Commission Form 4 filing. The transaction, which occurred on May 27, 2026, involved the exercise of vested stock options and their immediate sale, resulting in a weighted average price of $26.78 per share.
This disposal marks only the second open-market sale reported by Yea, with previous trades largely classified as administrative events. The immediate sale of exercised options means there was no net increase to Yea’s long-term common stock holdings. Following the transaction, Yea retains direct ownership of 229,918 shares, valued at approximately $6.16 million as of May 27, 2026.
The sale coincides with KalVista’s pending acquisition by Chiesi Group, which has offered $27 per share. The deal is expected to close in the third quarter of 2026. While Yea’s direct holdings have reduced by 28.84 per cent over the past year, the pace of outright sales remains limited, suggesting diminished available capacity rather than an escalation in discretionary selling.
KalVista’s lead drug, Ekterly, an oral plasma kallikrein inhibitor for hereditary angioedema, launched in July 2025 and generated $49 million in sales last year. The company and Chiesi intend to file for FDA approval to expand Ekterly’s use to children aged two through 11, targeting an underserved paediatric population.
Despite strong initial uptake, KalVista reported a loss of $109.5 million for the eight months ended December 31, 2025. Chiesi, an established business with a rare immunology-focused salesforce, expects the acquisition to generate strong profits. The Motley Fool’s Stock Advisor analyst team did not include KalVista in their current list of 10 best stocks to buy.
